Filtered By:
Cancer: Leukemia
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 266 results found since Jan 2013.
Hemorrhagic stroke due to leukostasis in pediatric mixed-phenotype acute leukemia
Blood Res. 2021 May 14. doi: 10.5045/br.2021.2021004. Online ahead of print.NO ABSTRACTPMID:33986185 | DOI:10.5045/br.2021.2021004
Source: Blood Research - May 14, 2021 Category: Hematology Authors: Shunsuke Yamamoto Yuhki Koga Kenichi Tetsuhara Noriyuki Kaku Hiroaki Ono Satoshi O Suzuki Toru Iwaki Shouichi Ohga Source Type: research
Long-term neurocognitive and quality of life outcomes in survivors of pediatric hematopoietic cell transplant
ConclusionsAlthough long-term survivors of pediatric HCT reported higher rates of impairment in specific neurocognitive domains, cognitive quality of life was perceived as similar to the general population. Subsets of survivors with certain co-morbidities had substantially worse neurocognitive outcomes.Implications for Cancer SurvivorsWhile the long-term impact of pediatric HCT can include neurocognitive deficits, survivors report average cognitive quality of life.
Source: Journal of Cancer Survivorship - June 4, 2021 Category: Cancer & Oncology Source Type: research
Molecules, Vol. 26, Pages 3943: CD47 in the Brain and Neurodegeneration: An Update on the Role in Neuroinflammatory Pathways
in Sahebkar
CD47 is a receptor belonging to the immunoglobulin (Ig) superfamily and broadly expressed on cell membranes. Through interactions with ligands such as SIRPĪ±, TSP-1, integrins, and SH2-domain bearing protein tyrosine phosphatase substrate-1 (SHPS-1), CD47 regulates numerous functions like cell adhesion, proliferation, apoptosis, migration, homeostasis, and the immune system. In this aspect, previous research has shown that CD47 modulates phagocytosis via macrophages, the transmigration of neutrophils, and the activation of T-cells, dendritic cells, and B-cells. Moreover, several studies have reported the in...
Source: Molecules - June 28, 2021 Category: Chemistry Authors: Seyed Mohammad Gheibihayat Ricardo Cabezas Nikita G. Nikiforov Tannaz Jamialahmadi Thomas P. Johnston Amirhossein Sahebkar Tags: Review Source Type: research
Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research
Prevalence and economic burden of major comorbidities in multiple sclerosis
ConclusionsOur study provides evidence of the burden of comorbidities in MS. Comorbidity is common in MS and produce additive costs.Key messagesThe use of administrative data for tracking the MS comorbidity could help knowledge gaps.When additivity situation is involved, preventive policies could lead to monetary savings.
Source: The European Journal of Public Health - October 20, 2021 Category: General Medicine Source Type: research
Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research
